Navigation Links
A microRNA prognostic marker identified in acute leukemia
Date:5/14/2012

COLUMBUS, Ohio A study has identified microRNA-3151 as a new independent prognostic marker in certain patients with acute leukemia. The study involves patients with acute myeloid leukemia and normal-looking chromosomes (CN-AML).

The study by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) found that when microRNA-3151 (miR-3151) is overexpressed in CN-AML, the disease responds poorly to treatment and patients experience shorter remissions and survival periods. This effect is independent of other gene mutations that may be present in the cells.

Additionally, miR-3151 is encoded within a gene called BAALC, which itself is an independent marker of poor survival when overexpressed in CN-AML.

The findings, published online in the journal Blood, provide new insights into the nature of AML and might in the future help determine the best therapy for individual patients and further personalize AML therapy.

"Patients with high levels of both miR-3151 and BAALC had the poorest outcome compared with those showing high expression of either miR-3151 or BAALC alone, or those expressing low levels of both," says principal investigator Dr. Clara D. Bloomfield, a Distinguished University Professor at Ohio State and cancer scholar and senior advisor to the OSUCCC James. "This suggests that miR-3151 and BAALC may act through different mechanisms to enhance poor outcome of CN-AML patients."

The study involved 179 patients aged 60 years or older with CN-AML who were treated on Cancer and Leukemia Group B (CALGB) clinical trials.

MicroRNAs are small molecules that cells use to help regulate the kinds and amount of proteins they make. About one-third of human microRNAs are encoded within host genes. Specifically, they are located in the portions of genes called introns, short stretches of DNA that are not used when genetic information is translated to make a protein.

"Very little is known about the regulation of microRNAs located within introns, and especially about their possible interactions with their host genes," says first author Dr. Ann-Kathrin Eisfeld, a post-doctoral researcher who works in the laboratory of study co-author Dr. Albert de la Chapelle and Bloomfield.

"This is the first description of interplay of an oncogene and its intronic, and possibly oncogenic, microRNA," Eisfeld says. "It may be the first of other important intronic microRNAs in leukemia and perhaps other malignancies."


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers identify key role of microRNAs in melanoma metastasis
2. Researchers find that inhibiting microRNAs may help prevent degenerative eye disorders
3. MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men
4. Protein and microRNA block cellular transition vital to metastasis
5. MicroRNAs could increase the risk of amputation in diabetics
6. MicroRNA-TP53 circuit connected to chronic lymphocytic leukemia
7. MicroRNA controls mammary gland development in mice
8. Caltech biologists discover microRNAs that control function of blood stem cells
9. MicroRNA molecule increases number of blood stem cells, may help improve cancer treatment
10. Cancer cells show rewired, fragmented microRNA networks
11. Study links microRNA to shut-down of DNA-repair genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Continually at the forefront of ... Drops™ have received the Non-GMO Project Verified seal. All five flavors of the ... only third-party verification for non-GMO foods and products in North America. , Available ...
(Date:6/28/2017)... VA (PRWEB) , ... June 28, 2017 , ... Guide ...      , No matter on which side of the Atlantic devicemakers do ... device regulations they have to follow. , In addition to the full text of ...
(Date:6/28/2017)... ... , ... Anyone with a remote control has seen the never-ending twists on the house flipping ... get rich in no time. But what about the buyers of the flipper's flip. ... of a flipped house. An email recently sent to Gary Case said, “Just closed ...
(Date:6/28/2017)... ... ... David B. Sosin, a founding partner at the law firm Sosin, Arnold & ... for the Illinois State Bar Association , in accordance with the organization’s rules of ... following a state-wide election and served in that capacity for the past year prior to ...
(Date:6/28/2017)... ... , ... American Farmer proudly announces the participation of Pure Line Seeds, Inc ... to broadcast fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... seed. As demand grew, the small company located in Moscow, Idaho extended its sales ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... Md. , June 7, 2017  Novavax, Inc., (Nasdaq: ... second of two Phase 2 trials of its RSV F ... of child bearing age have been published in the journal ... publication have been shared in prior scientific conferences). The Company ... in April 2014. Novavax is developing the RSV F Vaccine ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: